Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma

Br J Dermatol. 2022 Jan;186(1):15-16. doi: 10.1111/bjd.20821. Epub 2021 Nov 2.

Authors

G Blanchard¹, E Guenova^{1

2}

Affiliations

¹ Department of Dermatology, Lausanne University Hospital (CHUV) and the Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
² Department of Dermatology, University Hospital Zurich and the University of Zurich, Zurich, Switzerland.

PMID: 34988981
DOI: 10.1111/bjd.20821

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Exanthema* / chemically induced
Humans
Lymphoma*
Skin Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
mogamulizumab